Abstract: The role of norethindrone acetate (NA) in the management of adenomyosis was evaluated with a retrospective chart review of 28 premenopausal women between 27–49 years of age presenting with moderate to severe pelvic pain and bleeding. Bleeding and dysmenorrhea scores were analyzed using paired T-tests. There was significant improvement of both dysmenorrhea and bleeding after treatment. Age showed no correlation with dysmenorrhea or bleeding. Low dose NA could be considered an effective, well-tolerated and inexpensive medical alternative to surgery for treating symptomatic adenomyosis. Large multicentric studies may help validate our findings.
Keywords: norethindrone acetate; adenomyosis; dysmenorrhea
This is an open access article distributed under the
Creative Commons Attribution License which permits unrestricted use, distribution,
and reproduction in any medium, provided the original work is properly cited.
Export to BibTeX
MDPI and ACS Style
Muneyyirci-Delale, O.; Chandrareddy, A.; Mankame, S.; Osei-Tutu, N.; Gizycki, H. Norethindrone Acetate in the Medical Management of Adenomyosis. Pharmaceuticals 2012, 5, 1120-1127.
Muneyyirci-Delale O, Chandrareddy A, Mankame S, Osei-Tutu N, Gizycki H. Norethindrone Acetate in the Medical Management of Adenomyosis. Pharmaceuticals. 2012; 5(10):1120-1127.
Muneyyirci-Delale, Ozgul; Chandrareddy, Ashadeep; Mankame, Siddhi; Osei-Tutu, Nanna; Gizycki, Hans von. 2012. "Norethindrone Acetate in the Medical Management of Adenomyosis." Pharmaceuticals 5, no. 10: 1120-1127.